Search News Archives
Special Offers and Promotions
Conferences | Events
LGC acquires leading bioanalytical sciences business from Quotient Bioresearch
LGC and Quotient Bioresearch are pleased to announce that they have reached agreement on the sale by Quotient of its Bioanalytical Sciences division to LGC
Quotient Bioanalytical Sciences is a leading provider of bioanalytical services across the fields of small molecules, biomarkers, biopharmaceuticals and microbiological testing to customers in the pharmaceutical and biotechnology sectors. It is based at Fordham, Cambridgeshire.
The acquisition, which will form part of LGC’s Health Sciences division, will enable LGC to provide an enhanced range of products and services to the pharmaceutical sector including bioanalysis, materials science and reference materials amongst others.
Under the terms of the transaction, Quotient and LGC have committed to collaborate as preferred partners on the provision of Bioanalytical Sciences. This will enable clients to continue to benefit from the early development services offered by the Quotient group including clinical trials, metabolism and radiolabelling. The Bioanalytical Sciences business will continue to trade using the “Quotient” name under its new ownership for the time being.
The transaction follows the sale two years ago by Quotient to LGC of HFL Sport Science, which is also based at the Fordham site.
Jeremy Cook, Managing Director of LGC’s Health Sciences said, “We’re delighted to have acquired Quotient Bioanalytical Sciences, a high quality business which is complementary to our existing activities. We continue to develop our range of first-rate services in the pharmaceutical, biotechnology and agrochemical sectors by offering our customers a unique mix of technical experience, leading edge facilities and knowledgeable people.”
Dr Steve Pleasance, Managing Director of Quotient Bioanalytical Sciences said “LGC’s focus on complex analytical chemistry, high quality science and service delivery make them a natural home for our business. Both our organisations have reputations built upon quality and innovation and LGC’s global presence will help support the continued growth of services to our customers.”
For more about LGC visit www.lgcgroup.com
LGC (www.lgcgroup.com) is the international science-based company and market leader in the laboratory services, measurement standards, reference materials and proficiency testing marketplaces. LGC operates in a variety of international markets which underpin the safety, health and security of the public and the regulation of industry, for both private and public sector clients.
LGC has five divisions - LGC Standards, LGC Genomics, LGC Health Sciences, LGC Forensics and LGC Science & Technology. The latter includes specialist laboratories delivering contracts for the Department for Business, Innovation and Skills (BIS) and supports LGC's designated role as the UK's National Measurement Institute for chemical and biochemical measurement.
Its operations are extensively accredited to international quality standards such as ISO/IEC 17025. With headquarters in Teddington, South West London, the LGC Group employs over 1,800 staff, operating out of 22 countries, with laboratories and centres across Europe and the US, as well as sites in Brazil, China and India. The genesis of LGC dates back to 1842, and for more than 100 years it has been home to the UK statutory function of Government Chemist. Formerly the Laboratory of the Government Chemist, LGC was privatised in 1996 and is now majority-owned by funds managed by Bridgepoint.
About Quotient Bioresearch
Quotient Bioresearch (www.quotientbioresearch.com) is a leading provider of early stage and specialist drug development services to life science clients worldwide. The company provides tailored solutions for pharmaceutical, biotechnology and agrochemical clients, using state-of-the-art technologies underpinned by unparalleled medical, chemical and biological expertise. Its consultative, science-driven approach ensures the highest quality service to support and accelerate new product development. Its extensive range of capabilities spans Radiochemistry, Metabolism and Clinical. These can be provided independently or integrated into bespoke work programmes.